A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This is probably the last time I red thumb a company anywhere near $0.50. Although my pick is quickly approaching -400 points - by far my worst pick active or ever - I am sure the company will fall pretty far soon enough. If only I had followed zz's green thumb at the same entry point I could have enjoyed a swing of over 500 pts. $@!%! me
-650....crap.
Vindication! (Although it's really just luck since I red-thumbed without looking into the company's trials in the first place)
Can this company go away already? The leading drug candidate will likely never be successful. Add on the dilutive financing and you get the picture.
Not again! At -250 and holding steady for the next time someone calls out this company for data dredging. Combining the placebo and 1 mg groups and then comparing it to the 3 mg groups...really? Is patient data divided by days of the week and alphabetical mother's maiden name sub groups too?